Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Vildagliptin and Metformin Tablets vs GALVUS MET in Healthy Volunteers
NCT06248801Phase 1Not yet recruiting
- Sponsor
- Bio-innova
- Start
- Sep 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of vildagliptin and metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Bio-innova. Primary endpoints: Area under the plasma concentration-time curve from time zero to the last measurable concentration at 36 hours and Maximal measured plasma concentration at 36 hours. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
vildagliptinmetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06248801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06248801.